AcelRx Pharmaceuticals submits Zalviso NDA to FDA AcelRx Pharmaceuticals.

Related StoriesCombatting viral and bacterial lung attacks with volatile anesthetics: an interview with Dr ChakravarthyFDA accepts sNDA to review Brintellix scientific trial data for treatment of major depressive disorderAllergan settles patent litigation with Amneal related to NAMENDA XR prolonged release capsules The Zalviso NDA submission represents a significant milestone for AcelRx as we look for FDA approval for our first item candidate based on our proprietary sublingual sufentanil formulation and our delivery program technology, mentioned Richard King, cEO and president of AcelRx.People may delay visiting a health care provider This may be an inverse concern, because as people gain better access to health – related information in addition they become able to conveniently check and recognize the symptoms of an illness early on, rather than waiting until they obtain acute to see a doctor Overall, while some want to keep Wellness a ‘black container’, helping people find information and sign up for conversations about health issues that matter to them should be welcomed as a positive switch. Concerns about self-diagnosis, self-medication and privacy can’t be ignored, but the best way to address them can be education, not censorship.